Weekly paclitaxel and 5-fluorouracil in pretreated patients with metastatic breast cancer: A phase I study

Enrico Cortesi, Federico Grifalchi, Sara Ramponi, Augusto Padovani, Andrea Mancuso, Luca Paoluzzi, Francesco Ferrau, Annalisa Oliva

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Recent studies have shown a good activity/tolerability for weekly paclitaxel and 5-fluorouracil in protracted continuous infusion (p.c.i.) in metastatic breast cancer patients pretreated with anthracyclines. Materials and Methods: To define the MTD of weekly paclitaxel (days 1-8-15-22, every 4 weeks with a starting dose of 75 mg/m2 and subsequent dose escalation: 90 mg/m2 and 105 mg/m2) in combination with a fixed dose of 5-fluorouracil in p.c.i. (250 mg/m2/day for 3 weeks + 1 week of rest). Results: Eleven patients were enrolled; on Step III two patients experienced DLT (1 G 3 mucositis and 1 febrile neutropenia). G 3-4 toxicities were: G 3 mucositis (2 out of 11), G 3-4 neutropenia (1 out of 11). Conclusion: The recommended schedule for phase II studies is: paclitaxel 90 mg/m2/w + 5-fluorouracil 250 mg/m2 in p.c.i. for 21 days. This is the first phase I trial with the combination of weekly paclitaxel and 5-fluorouracil p.c.i. in advanced breast cancer patients.

Original languageEnglish (US)
Pages (from-to)1961-1966
Number of pages6
JournalAnticancer Research
Volume23
Issue number2 C
StatePublished - Mar 1 2003
Externally publishedYes

Fingerprint

Paclitaxel
Fluorouracil
Breast Neoplasms
Mucositis
Febrile Neutropenia
Anthracyclines
Neutropenia
Appointments and Schedules

Keywords

  • Fluorouracil
  • Metastatic breast cancer
  • Paclitaxel
  • Phase I

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cortesi, E., Grifalchi, F., Ramponi, S., Padovani, A., Mancuso, A., Paoluzzi, L., ... Oliva, A. (2003). Weekly paclitaxel and 5-fluorouracil in pretreated patients with metastatic breast cancer: A phase I study. Anticancer Research, 23(2 C), 1961-1966.

Weekly paclitaxel and 5-fluorouracil in pretreated patients with metastatic breast cancer : A phase I study. / Cortesi, Enrico; Grifalchi, Federico; Ramponi, Sara; Padovani, Augusto; Mancuso, Andrea; Paoluzzi, Luca; Ferrau, Francesco; Oliva, Annalisa.

In: Anticancer Research, Vol. 23, No. 2 C, 01.03.2003, p. 1961-1966.

Research output: Contribution to journalArticle

Cortesi, E, Grifalchi, F, Ramponi, S, Padovani, A, Mancuso, A, Paoluzzi, L, Ferrau, F & Oliva, A 2003, 'Weekly paclitaxel and 5-fluorouracil in pretreated patients with metastatic breast cancer: A phase I study', Anticancer Research, vol. 23, no. 2 C, pp. 1961-1966.
Cortesi E, Grifalchi F, Ramponi S, Padovani A, Mancuso A, Paoluzzi L et al. Weekly paclitaxel and 5-fluorouracil in pretreated patients with metastatic breast cancer: A phase I study. Anticancer Research. 2003 Mar 1;23(2 C):1961-1966.
Cortesi, Enrico ; Grifalchi, Federico ; Ramponi, Sara ; Padovani, Augusto ; Mancuso, Andrea ; Paoluzzi, Luca ; Ferrau, Francesco ; Oliva, Annalisa. / Weekly paclitaxel and 5-fluorouracil in pretreated patients with metastatic breast cancer : A phase I study. In: Anticancer Research. 2003 ; Vol. 23, No. 2 C. pp. 1961-1966.
@article{9ceed63ff45c49279bf00a04838ad720,
title = "Weekly paclitaxel and 5-fluorouracil in pretreated patients with metastatic breast cancer: A phase I study",
abstract = "Background: Recent studies have shown a good activity/tolerability for weekly paclitaxel and 5-fluorouracil in protracted continuous infusion (p.c.i.) in metastatic breast cancer patients pretreated with anthracyclines. Materials and Methods: To define the MTD of weekly paclitaxel (days 1-8-15-22, every 4 weeks with a starting dose of 75 mg/m2 and subsequent dose escalation: 90 mg/m2 and 105 mg/m2) in combination with a fixed dose of 5-fluorouracil in p.c.i. (250 mg/m2/day for 3 weeks + 1 week of rest). Results: Eleven patients were enrolled; on Step III two patients experienced DLT (1 G 3 mucositis and 1 febrile neutropenia). G 3-4 toxicities were: G 3 mucositis (2 out of 11), G 3-4 neutropenia (1 out of 11). Conclusion: The recommended schedule for phase II studies is: paclitaxel 90 mg/m2/w + 5-fluorouracil 250 mg/m2 in p.c.i. for 21 days. This is the first phase I trial with the combination of weekly paclitaxel and 5-fluorouracil p.c.i. in advanced breast cancer patients.",
keywords = "Fluorouracil, Metastatic breast cancer, Paclitaxel, Phase I",
author = "Enrico Cortesi and Federico Grifalchi and Sara Ramponi and Augusto Padovani and Andrea Mancuso and Luca Paoluzzi and Francesco Ferrau and Annalisa Oliva",
year = "2003",
month = "3",
day = "1",
language = "English (US)",
volume = "23",
pages = "1961--1966",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2 C",

}

TY - JOUR

T1 - Weekly paclitaxel and 5-fluorouracil in pretreated patients with metastatic breast cancer

T2 - A phase I study

AU - Cortesi, Enrico

AU - Grifalchi, Federico

AU - Ramponi, Sara

AU - Padovani, Augusto

AU - Mancuso, Andrea

AU - Paoluzzi, Luca

AU - Ferrau, Francesco

AU - Oliva, Annalisa

PY - 2003/3/1

Y1 - 2003/3/1

N2 - Background: Recent studies have shown a good activity/tolerability for weekly paclitaxel and 5-fluorouracil in protracted continuous infusion (p.c.i.) in metastatic breast cancer patients pretreated with anthracyclines. Materials and Methods: To define the MTD of weekly paclitaxel (days 1-8-15-22, every 4 weeks with a starting dose of 75 mg/m2 and subsequent dose escalation: 90 mg/m2 and 105 mg/m2) in combination with a fixed dose of 5-fluorouracil in p.c.i. (250 mg/m2/day for 3 weeks + 1 week of rest). Results: Eleven patients were enrolled; on Step III two patients experienced DLT (1 G 3 mucositis and 1 febrile neutropenia). G 3-4 toxicities were: G 3 mucositis (2 out of 11), G 3-4 neutropenia (1 out of 11). Conclusion: The recommended schedule for phase II studies is: paclitaxel 90 mg/m2/w + 5-fluorouracil 250 mg/m2 in p.c.i. for 21 days. This is the first phase I trial with the combination of weekly paclitaxel and 5-fluorouracil p.c.i. in advanced breast cancer patients.

AB - Background: Recent studies have shown a good activity/tolerability for weekly paclitaxel and 5-fluorouracil in protracted continuous infusion (p.c.i.) in metastatic breast cancer patients pretreated with anthracyclines. Materials and Methods: To define the MTD of weekly paclitaxel (days 1-8-15-22, every 4 weeks with a starting dose of 75 mg/m2 and subsequent dose escalation: 90 mg/m2 and 105 mg/m2) in combination with a fixed dose of 5-fluorouracil in p.c.i. (250 mg/m2/day for 3 weeks + 1 week of rest). Results: Eleven patients were enrolled; on Step III two patients experienced DLT (1 G 3 mucositis and 1 febrile neutropenia). G 3-4 toxicities were: G 3 mucositis (2 out of 11), G 3-4 neutropenia (1 out of 11). Conclusion: The recommended schedule for phase II studies is: paclitaxel 90 mg/m2/w + 5-fluorouracil 250 mg/m2 in p.c.i. for 21 days. This is the first phase I trial with the combination of weekly paclitaxel and 5-fluorouracil p.c.i. in advanced breast cancer patients.

KW - Fluorouracil

KW - Metastatic breast cancer

KW - Paclitaxel

KW - Phase I

UR - http://www.scopus.com/inward/record.url?scp=0037862041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037862041&partnerID=8YFLogxK

M3 - Article

C2 - 12820487

AN - SCOPUS:0037862041

VL - 23

SP - 1961

EP - 1966

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2 C

ER -